Targeting the mutation in gliomas by CRISPR/Cas precision base editing.

Publication

Targeting the mutation in gliomas by CRISPR/Cas precision base editing.

Journal Paper/Review - Nov 2, 2024

Weber Remi, Vasella Flavio, Klimko Artsiom, Silginer Manuela, Lamfers Martine, Neidert Marian Christoph, Regli Luca, Schwank Gerald, Weller Michael

Citation

Weber R, Vasella F, Klimko A, Silginer M, Lamfers M, Neidert M, Regli L, Schwank G, Weller M. Targeting the mutation in gliomas by CRISPR/Cas precision base editing. Neurooncol Adv 2024; 6:vdae182.

Type

Journal Paper/Review (English)

Journal

Neurooncol Adv 2024; 6

Publication Date

Nov 2, 2024

Issn Electronic

2632-2498

Pages

vdae182

Brief description/objective

Gliomas, the most frequent malignant primary brain tumors, lack curative treatments. Understanding glioma-specific molecular alterations is crucial to develop novel therapies. Among them, the biological consequences of the isocitrate dehydrogenase 1 gene mutation ( ) remain inconclusive despite its early occurrence and widespread expression.